Roche to study remdesivir/Actemra cocktail against severe COVID-19 pneumonia

Swiss drugmaker Roche said on Thursday it would study its anti-inflammation drug Actemra mixed with Gilead Sciences Inc's remdesivir in hospitalised patients with severe COVID-19 pneumonia in a global trial of around 450 patients.